ADial Pharmaceuticals

18 articles with ADial Pharmaceuticals

• Adial Pharmaceuticals Announces FDA Reactivation of its Investigational New Drug Application for AD04 in Alcohol Use Disorder

  10/21/2020

  Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, announced that the U.S. Food and Drug Administration has reactivated Adial's U.S. Investigational New Drug application and lifted the clinical hold from AD04, a genetically-targeted therapeutic agent for the treatment of Alcohol Use Disorder.

• Adial Pharmaceuticals Announces Sale of 10,000 COVID-19 Antibody Rapid Test Devices

  9/30/2020

  Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received an initial firm order for the purchase of 10,000 Assure/FaStep® COVID-19 IgG/IgM Rapid Test Devices from a California-based technology corporation

• Adial Pharmaceuticals Announces COVID-19 Point-of-Care Antibody Test Granted First Ever FDA Emergency Use Authorization for Use with Fingerstick Blood Samples

  9/29/2020

  Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that the U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the Assure COVID-19 IgG/IgM Rapid Test Device.

• Adial Pharmaceuticals Files for Expedited Review of AD04 with the FDA

  9/25/2020

  Adial Pharmaceuticals, Inc. today announced that it has submitted a formal request to the U.S. Food and Drug Administration (FDA) in support of that AD04 should be considered eligible for an FDA expedited review program.

• Adial Pharmaceuticals and iRemedy Partner to Sell COVID-19 Antibody Test Kits to U.S. Medical Providers and Commence Sales

  9/22/2020

  Adial Pharmaceuticals, Inc.today announced that the two companies have commenced sales of FaStep COVID-19 IgG/IgM rapid antibody test kits to healthcare providers and hospitals through the iRemedy network and ecommerce platform.

• Adial Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16th

  9/9/2020

  Adial Pharmaceuticals, Inc. today announced that it will be presenting at the H.C. Wainwright Annual Global Investment Conference, being held virtually on September 14-16, 2020.

• Adial Pharmaceuticals to Present at The LD Micro 500 Virtual Conference on September 2nd

  9/1/2020

  Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it will be presenting at the LD Micro 500 Virtual Investor conference being held virtually on September 1-4, 2020.

• Adial Pharmaceuticals Announces Third-Party Sales and Distribution Agreement with Brik for Rapid Result COVID-19 Antibody Test Kits Thursday, August 6, 2020 9:30 AM

  8/6/2020

  Adial Pharmaceuticals, Inc. today announced that it has entered into an agreement with Brik LLC , an independent sales and marketing firm, to act as a third-party agent to Adial for the sale and distribution of Rapid Result COVID-19 antibody test kits.

• Adial Pharmaceuticals Schedules Business and Clinical Update Conference Call

  7/28/2020

  Developments to be Shared by Dr. Jack Reich, Director, Dr. Bankole A. Johnson, Chief Medical Officer, William B. Stilley, III, Chief Executive Officer, and Joseph A. M. Truluck, Chief Financial Officer

• Adial Pharmaceuticals Receives European Medicines Agency (EMA) Agreement on the Pediatric Investigation Plan (PIP) for AD04 in Alcohol Use Disorder

  7/22/2020

  Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, is pleased to report that the European Medicines Agency (EMA) has accepted its Pediatric Investigation Plan (PIP)

• Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia

  7/6/2020

  Adial Pharmaceuticals, Inc. today announced that it has received approvals in Sweden and Estonia to commence the Company's landmark ONWARD™ pivotal Phase 3 clinical trial to investigate its lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes.

• Adial Pharmaceuticals Announces Commencement of Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland

  6/26/2020

  Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has commenced its landmark ONWARD™ pivotal Phase 3 clinical trial in Poland to investigate its lead drug candidate, AD04,

• Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland

  6/16/2020

  Adial Pharmaceuticals, Inc. announced that it has received all necessary approvals to commence its landmark ONWARD™ pivotal Phase 3 clinical trial in Poland to investigate its lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder in persons with certain target genotypes related to the serotonin transporter and receptor genes.

• Adial Pharmaceuticals Closes Previously Announced $5.2 Million Registered Direct Offering

  6/15/2020

  Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a biopharmaceutical company focused on the development of treatments for addiction and currently conducting the ONWARD™ pivotal Phase 3 clinical trial of its lead drug candidate, AD04,

• ADial Pharmaceuticals Announces Issuance Of First U.S. Patent

  5/1/2014

• ADial Pharmaceuticals' Chairman, Bankole A. Johnson, To Head University of Marseille School of Medicine's New Brain Science Research Consortium

  2/20/2014

• ADial Pharmaceuticals Announces Strategic Partnership With Cato BioVentures

  11/5/2013

• ADial Pharmaceuticals' Chairman, Bankole A. Johnson, Accepts Position at the University of Maryland School of Medicine

  8/22/2013